4D Molecular Therapeutics, Inc. (FDMT)

4D Molecular Therapeutics, Inc. (FDMT) is a healthcare company (biotechnology) based in the United States. The share price is $10.65, down 5.66% on the day, which values the company at $600.5M. Price as of 17 Nov 2026, 17:30 UTC, from Yahoo Finance.

Key facts

Share price
$10.65−5.66% today
Market value
$600.5M
Funk Score
58/100
Against its own history
Well below its usual priceusual price $34.79
200-week average
$13.0318% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

4D Molecular Therapeutics, Inc. in more detail

FDMT trades at -2.5× next year's expected earnings, 6.3× sales. Measured against its own history, the price is 69% below what its usual multiples would imply ($34.79) — well below its usual price. It sits 18% below its 200-week average of $13.03.

Over the last five fiscal years 4D Molecular Therapeutics, Inc. has compounded revenue 44.8% a year. Its Funk Score is 58 out of 100 (financial strength 7.6, profitability 2.0, growth 8.7, value 5.0, each out of 10).

In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Share count keeps rising; Heavy stock-based pay.

1 of the superinvestors tracked here hold FDMT, including Peter Kolchinsky (0.6% of the portfolio).

Superinvestors holding FDMT

1 of the investors tracked here report a position in their latest 13F filing.

4D Molecular Therapeutics, Inc. (FDMT): questions and answers

What is 4D Molecular Therapeutics, Inc.'s market cap?

4D Molecular Therapeutics, Inc. is valued at $600.5M at a share price of $10.65.

Is FDMT overvalued or undervalued?

Against its own history, FDMT is well below its usual price: the price is 69% below the $34.79 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is FDMT above its 200-week moving average?

No. FDMT is 18.2% below its 200-week average of $13.03. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is 4D Molecular Therapeutics, Inc. growing?

Over the last five fiscal years 4D Molecular Therapeutics, Inc.'s revenue grew 44.8% a year.

Does FDMT pay a dividend?

4D Molecular Therapeutics, Inc. does not currently pay a regular dividend.

Which famous investors own FDMT?

In their latest quarterly filings, Peter Kolchinsky (0.6% of the portfolio) hold FDMT. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “4D Molecular Therapeutics, Inc. (FDMT) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/FDMT

Underlying data: Yahoo Finance; company filings with the SEC.